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Objective: Although cardiac transplantation has been performed for complete re-
moval of ventricular tumors, complete surgical resection with ventricular recon-
struction is desirable. Thus patients with benign tumors would probably be cured,
and those with malignant tumors would have a better prognosis. In this study
extensive and complete surgical resection of ventricular tumors is followed by
anatomic and functional ventricular reconstruction with a dynamic cardiomyoplasty
procedure.
Methods: Seven patients (mean age, 32.7 years) underwent complete resection of
ventricular tumors. Histologic types were distributed as follows: fibroma in 2
patients and sarcoma, lymphosarcoma, hemangioma, lipoma, and metastatic angio-
sarcoma, respectively, in the remaining 5 patients. Six of the patients were consid-
ered candidates for heart transplantation because of the extent of tumor invasion.
Surgery consisted of 4 steps: (1) tumor resection; (2) coronary artery resection
(when invaded by the tumor) and coronary artery bypass grafting; (3) valvular
reconstruction (when possible) or replacement; and (4) ventricular wall reconstruc-
tion with a pericardial patch for closure of the ventricular defect (neoendocardium)
covered by the electrostimulated latissimus dorsi muscle flap (neomyocardium).
Results: All patients survived surgical intervention, but 2 late postoperative deaths
are reported. Among the surviving patients, early complications played a major role
in their postoperative course and consisted of arrhythmias, atrioventricular block
necessitating a dual-chamber pulse generator, respiratory insufficiency, and heart
failure. Two patients were assisted postoperatively with an intra-aortic balloon
pump. On postoperative follow-up (mean, 72.4  8.5 months), an improvement in
the patients’ functional status was observed. Patients moved from a mean New York
Heart Association functional class of 2.8 to a mean functional class of 1.2.
Conclusions: The excellent long-term evolution without recurrence, ventricular
dysfunction, and/or thromboembolic complications implies that cardiomyoplasty
could be recommended as an alternative to heart transplantation for the therapy of
large ventricular tumors.
Cardiac tumors are generally rare, with an incidence ranging from0.0017% to 0.03% at postmortem examinations in different series.1Ventricular tumors are distinctly rare, and of all primary tumors ofthe heart, those of ventricular origin represent fewer than 10%.2Metastatic disease of the heart is far more common and has beenfound at autopsy in up to 21% of patients with cancer. Approxi-
mately 75% of primary cardiac tumors are benign, and 25% are malignant.3,4
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Although cardiac transplantation has been performed for
complete removal of ventricular tumors, complete surgical
resection with ventricular reconstruction is desirable, inso-
far as that patients with benign tumors would probably be
cured,5,6 whereas those with malignant tumors would have
a better prognosis. In the following study, extensive and
complete surgical resection of ventricular tumors was fol-
lowed by anatomic ventricular reconstruction with a cardio-
myoplasty procedure. Our clinical experience in 7 patients
is presented with long-term follow-up from 3 to 15 years for
the surgical treatment of ventricular tumors.
Methods
At the Department of Cardiac Surgery of Broussais Hospital, the
medical records and diagnostic test results of 92 patients present-
ing with cardiac tumors between September 1985 and June 2000
were examined. Of these patients, 33 (18 women) had myxomas,
and all of them were adults (mean age, 58.1  18.2 years).
Fifty-nine patients (33 women) had other types of tumors (mean
age, 45.6  17.9 years). Preoperative diagnosis was made by
means of echocardiography, magnetic resonance imaging, angiog-
raphy, and tumor biopsy. The presence or absence of metastases
was generally assessed by means of computed tomography. Seven
patients underwent complete resection of ventricular tumors, with
anatomic reconstruction by means of dynamic cardiomyoplasty.
Six of these patients were considered candidates for heart trans-
plantation because of the extent of the tumor invasion. All patients
were followed up at our institution after hospital discharge. The
group of patients undergoing resection followed by cardiomyo-
plastic reconstruction had a mean follow-up of 72.4 months.
Patient Population
Seven adult patients (4 women and 3 men; mean age, 32.7 years;
age range, 22-55 years; mean weight, 66.9  10.17 kg; mean
height, 168  6.11 cm) underwent tumor resection and the car-
diomyoplasty procedure. The most common clinical symptoms
were syncopal events, tachyarrhythmias, and heart failure. Cardiac
tumors were primary in 6 patients, and metastatic disease in 1
patient. The distribution of histologic types was fibroma in 2
patients (Figure 1) and sarcoma, lymphosarcoma, hemangioma,
lipoma, and metastatic angiosarcoma, respectively, in the remain-
ing 5 patients (Table 1).
Surgical Technique: Principles for Tumor Resection
and Ventricular Reconstruction
Tumor resection. The advantage of using the cardiomyoplasty
approach after tumor resection is that the tumor can be extensively
resected, including the borders, to avoid leaving atypical cells.
During cardiopulmonary bypass, the resection includes normal
myocardial tissue strong enough to suture a pericardial patch, so as
to close the ventricular cavity. The complementary latissimus dorsi
muscle (LDM) cardiomyoplasty restores myocardial function, pre-
serving normal systolic and diastolic functions.
Coronary artery resection. If the main branches of the coro-
nary arteries are involved by the tumor, the approach includes
resection of a segment of the arteries. In all cases requiring
coronary artery resection, postoperative coronary perfusion is en-
sured by a coronary artery bypass graft. If the coronary sinus is
involved by the tumor, the feasibility of the tumor resection must
be carefully evaluated.
Valvular resection or reconstruction. When the cardiac
valves are invaded, our approach is to preserve both valvular and
subvalvular structures whenever possible. In some cases of partial
tumor invasion of the mitral or tricuspid valve, the leaflet may be
excised from the anulus. Then the leaflets are reimplanted after
tumor resection and reinforced with a prosthetic annuloplasty ring.
When the valve is extensively invaded by a tumor, it should be
replaced with a prosthetic valve.
Ventricular wall reconstruction. The residual defect resulting
from tumor resection can be closed, maintaining an adequate
residual ventricular chamber. The LDM flap is then used to cover
this area, reenforcing the ventricular sutures (Figure 2). However,
in most of the patients operated on by our group, the ventricular
defects were very large. For these patients, the approach consisted
of closing the ventricular cavity by using an autologous pericardial
patch (immersed for 10 minutes in a 0.6% glutaraldehyde solu-
tion). The pericardial patch was fixed to the ventricular borders
with a running Prolene 4-0 suture (Ethicon, Inc, Somerville, NJ),
and the LDM flap was fixed over the residual myocardium and
pericardial patch. In this manner an anatomic reconstruction was
performed, with the pericardial patch representing the neoendo-
cardium and the electrostimulated LDM representing the neomyo-
cardium. An adequate ventricular cavity was preserved by using
Figure 1. Macroscopic view of right ventricular fibroma requiring
tricuspid valve annuloplasty, right coronary artery bypass, and
cardiomyoplasty after resection (patient 3).
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Figure 2. Fibroma weighing 1.4 kg invading the diaphragmatic wall of both ventricles (patient 1).
Figure 3. Magnetic resonance image showing the right ventricle infiltrated by an angiosarcoma in a 22-year-old
woman (patient 7).
TABLE 1. Preoperative status
Patient
No.
Age
(y) Sex
Weight
(kg)
Height
(cm) Histology Origin Symptoms
1 38 F 62 165 Fibroma LV RV HF
2 55 M 78 170 Lymphosarcoma RA RV HF RI
3 22 F 53 161 Fibroma RV VA
4 26 M 80 176 Hemangioma VS HF VA
5 38 M 72 176 Rhabdosarcoma RV VS HF
6 28 F 58 163 Lipoma LV PC
7 22 F 65 165 Angiosarcoma RA RV HF
LV, Left ventricle; RV, right ventricle; HF, heart failure; RA, right atrium; RI, respiratory insufficiency; VA, ventricular arrhythmias; VS, ventricular septum;
PC, pain in the chest.
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this technique. A pulse train generator (Cardio-Myostimulator;
Medtronic, Minneapolis, Minn) was used to deliver synchronous
systolic pulses by means of left ventricular electrodes connected to
the sensing pacemaker chamber and 2 latissimus dorsi intramus-
cular electrodes coupled to the pacing chamber. The LDM elec-
trostimulation started at postoperative week 2. After 2 months, the
patients were stimulated with a 6-pulse burst and a heart/muscle
ratio of 2:1.
Associated Surgical Procedures
All patients underwent combined surgical procedures because of
the extensive and invasive nature of the tumors. These procedures
included tricuspid valve annuloplasty or replacement, mitral valve
replacement, posterior descending coronary artery bypass grafting,
pulmonary valve annuloplasty, reconstruction of septal defects,
and atrioventricular pacemaker implantation (Tables 2 and 3).
Results
All patients survived surgical intervention, but 2 late post-
operative deaths occurred. The first patient, given a diagno-
sis of lymphoma, died on postoperative day 45 as a result of
sepsis. The second patient, with a sarcoma, died on postop-
erative day 8 because of aortic bleeding originating from a
portion of the aorta invaded by the tumor. The 5 survivors
could benefit from a complete resection of the ventricular
tumors confirmed by means of histopathologic studies. The
margins of the resected myocardium were free of tumor
cells. Among the surviving patients, early complications
played a major role during their postoperative course and
consisted of arrhythmia, atrioventricular block necessitating
a dual-chamber pulse generator, respiratory insufficiency,
and heart failure. Two patients were assisted postopera-
tively with an intra-aortic balloon pump. Patients 5 and 7
underwent preoperative chemotherapy, and patient 5 was
followed up with postoperative chemotherapy. In patient 7
residual tumor cells were observed in histologic studies.
This patient died on postoperative day 8 (Figure 3). On
follow-up (mean of 72.4 months postoperatively), an im-
provement in the patients’ functional status was observed.
Patients moved from preoperative New York Heart Asso-
ciation functional class II to IV (mean, 2.8) to postoperative
functional class I (mean, 1.2), with attenuation of symp-
toms. No thromboembolic complications were observed.
Clinical follow-up, adjuvant therapy, and tumor recurrence
are included in Table 4.
Discussion
The prognosis of patients with primary malignant cardiac
tumors is dismal, with death occurring within 6 months
regardless of the histologic diagnosis.5,7 The treatment of
Figure 4. Electron beam scanner showing the invasion of the ventricular septum and right ventricular wall by a
rhabdosarcoma (patient 5).
TABLE 2. Surgical procedures
Excision
Ventricular
reconstruction Associated procedures
Complete CMP Diaphragm plasty
Complete CMP PP TV plasty PDA bypass
Complete CMP PP TV plasty PA
plasty PDA bypass
Complete CMP PP TV plasty VSD
repair AV pacemaker
Complete CMP PP VSD repair
Complete CMP PP MV replacement
Incomplete CMP PP TV replacement PDA
bypass
CMP, Cardiomyoplasty; PP, pericardial patch; TV, tricuspid valve; PDA,
posterior descending artery; PA, pulmonary artery; AV, atrioventricular;
VSD, ventricular septal defect; MV, mitral valve.
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primary malignant cardiac tumors is complex and difficult
because of the aggressive biologic characteristics of these
tumors and the limited experience of any one center in the
management of these lesions.5 Bear and Moodie8 reviewed
11 patients with malignant cardiac tumors, 10 of whom had
died at the time of their report, with an average of 9 months
from the time of diagnosis to death. Putnam and associates9
demonstrate no significant difference in survival of patients
with primary malignant sarcomas of the heart who under-
went surgical intervention alone compared with those who
had adjuvant postoperative chemotherapy.
According to Murphy and coworkers,1 patients who have
potentially resectable disease are rare. They described 12
patients with primary cardiac sarcomas of a total of 114
patients with primary tumors of the heart. Survival was 9
months, but palliation was good. Most patients died of
metastatic disease. Beghetti and colleagues10 believe that if
total excision is not possible, partial resection may be ben-
eficial. They report a case of an infant who underwent
partial excision of a fibroma and creation of a bidirectional
cavopulmonary shunt. Jamieson and associates11 have re-
ported transplantation in a 17-year-old patient with an un-
resectable left ventricular fibroma, whereas Aravot and co-
workers12 described a patient who did well 5 years after
orthotopic transplantation for a neurofibrosarcoma of the
heart. The actual number of primary cardiac tumors is small,
and the number that are treatable by means of orthotopic
transplantation is even smaller.13,14 Reece and colleagues6
described 20 patients who underwent surgery at the Texas
Heart Institute for primary tumors other than myxomas.
This series confirms the poor results obtained with primary
malignant cardiac tumors and indicates that metastases usu-
ally cause death within a year.
Concerning benign cardiac tumors, the diagnosis in
many cases is achieved when the tumor mass is large,
producing malignant arrhythmias and hemodynamic decom-
pensation.15 At this stage, surgical resection may be difficult
and followed by hemodynamic decompensation because of
the small ventricular chambers, resulting from the resection
and ventricular closure.
The role of cardiomyoplasty in patients with large ven-
tricular tumors is based on the principle that this procedure
offers the possibility of reconstructing a contractile ventric-
ular wall, thus preserving an adequate size and shape of the
ventricular residual cavities. Moreover, in malignant tumors
this technique allows a large resection of the disease without
recurrence, avoiding heart transplantation (Figure 4).
In our institution we selected only 7 patients from a
series of 59 patients (excluding 33 myxomas) to perform
cardiomyoplasty after cardiac tumor resection. In our expe-
rience the size and localization of these tumors and the
estimated residual ventricular volumes would result in a
difficult operative and postoperative problem, with high risk
for anatomic and functional complications.
Clinical limits for the indication of cardiomyoplasty in
patients presenting with ventricular tumors would be the
invasion of the coronary sinus, as well as more than 50% of
the ventricular chambers. Extensive invasion of the ventric-
ular septum should also be an exclusion criteria for cardio-
TABLE 3. Tumor dimensions and ventricular function
Patient
Tumor
dimensions
(cm) Patch size (cm)
Preoperative
LVEF (%)
Postoperative
LVEF (%)
Preoperative
RVEF (%)
Postoperative
RVEF (%)
1 28 20 10 No patch (endocardium
preserved)
23 38 20 27
2 9 7 5 5 4 37 * 15 *
3 7 7 7 5 5 40 55 10 32
4 6 6 6 4 3 28 64 25 37
5 8 9 4 6 5 44 54 26 35
6 8 5 3 6 4 48 56 21 32
7 13 8 7 7 6 58 † 16 †
Normal values measured with MUGA scan: left ventricle, greater than 50%; right ventricle, greater than 30%. LVEF, Left ventricular ejection fraction; RVEF,
right ventricular ejection fraction.
*Patient died at postoperative month 2.
†Patient died at postoperative week 2.
TABLE 4. Adjuvant tumoral therapy and clinical follow-up
Patient Adjuvant therapy
Follow-up
(mo) NYHA FC Clinical status
1 Antiarrhythmics 181 I Full active
2 — — — Died
3 — 109 I Delivered 2 babies
4 Cardiac pacing 99 I Full active
5 Chemotherapy 75 II Asymptomatic
6 — 46 I Full active (athletics)
7 Chemotherapy — — Died
FC, Functional class.
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myoplasty because the role of the ventricular septum is of
capital importance for cardiomyoplasty. Physiologically,
the newly reconstructed ventricular wall is hemodynami-
cally integrated with a still active ventricular septum. In
patients with malignant tumors, regression of tumoral vol-
ume in response to alternative or adjuvant therapies to
surgical intervention (chemotherapy or radiotherapy) should
be carefully evaluated before cardiomyoplasty.
Latissimus dorsi dynamic cardiomyoplasty has been per-
formed worldwide in more than 1500 patients.16 Most of the
indications include patients with ischemic (50%) and idio-
pathic cardiomyopathies (50%). We found that cardiomyo-
plasty is well adapted to reconstruct the ventricular cham-
bers after tumor resection.16-18 Historically, it was necessary
to adapt this technique for this disease.18 In this manner the
rationale was to create a new ventricular wall by using
autologous pericardium to replace the endocardium, taking
advantage of its hemocompatibility. The electrostimulated
LDM was used to replace the resected myocardium. Our
surgical approach to reconstruct ventricular chambers after
tumor resection is to preserve a maximum of the anatomic
and functional characteristics of each ventricle, including
the valvular apparatus and a compliant ventricular chamber.
The excellent long-term evolution without recurrence, ven-
tricular dysfunction, and/or thromboembolic complications
implies that cardiomyoplasty could be recommended as an
alternative to heart transplantation for therapy of large ven-
tricular tumors.
We thank Theano Irinopoulou, PhD, for her assistance in the
statistical analysis of our data.
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